These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 17899911)

  • 1. Selecting anti-infective agents for the treatment of bone infections.
    Venugopalan V; Smith KM; Young MH
    Orthopedics; 2007 Sep; 30(9):713-7. PubMed ID: 17899911
    [No Abstract]   [Full Text] [Related]  

  • 2. [Use of ciprofloxacin in the treatment and prevention of surgical infections].
    Iakovlev VP
    Antibiot Khimioter; 1999; 44(7):38-44. PubMed ID: 10494382
    [No Abstract]   [Full Text] [Related]  

  • 3. Implantable antimicrobial biomaterials for local drug delivery in bone infection models.
    Caplin JD; García AJ
    Acta Biomater; 2019 Jul; 93():2-11. PubMed ID: 30654212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and clinical studies of T-3761 in otorhinolaryngeal infections.
    Shinkawa A; Kimura H; Sakai M; Miyake H
    Drugs; 1995; 49 Suppl 2():401-2. PubMed ID: 8549377
    [No Abstract]   [Full Text] [Related]  

  • 5. [The place of fluoroquinolones in the treatment of bacterial infections].
    Iakovlev SV
    Antibiot Khimioter; 1999; 44(12):27-30. PubMed ID: 10687031
    [No Abstract]   [Full Text] [Related]  

  • 6. Innovative strategies for combating biofilm-based infections.
    Melander RJ; Melander C
    Adv Exp Med Biol; 2015; 831():69-91. PubMed ID: 25384664
    [No Abstract]   [Full Text] [Related]  

  • 7. [Pharmacokinetic basis for the use of pefloxacin in severe forms of infectious-inflammatory diseases].
    Navashin PS; Smirnova LB
    Antibiot Khimioter; 1998; 43(12):30-8. PubMed ID: 10079873
    [No Abstract]   [Full Text] [Related]  

  • 8. [Antibiotic strategy in an infectious diseases unit].
    Dupon M
    Presse Med; 2000 Jan; 29(2):121-3. PubMed ID: 10682044
    [No Abstract]   [Full Text] [Related]  

  • 9. Ertapenem for osteoarticular infections in obese patients: a pharmacokinetic study of plasma and bone concentrations.
    Chambers J; Page-Sharp M; Salman S; Dyer J; Davis TME; Batty KT; Manning L
    Eur J Clin Pharmacol; 2019 Apr; 75(4):511-517. PubMed ID: 30511329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Fluoroquinolones--a current review].
    Christ W; Kemmler H
    Med Monatsschr Pharm; 2001 Jul; 24(7):215-25. PubMed ID: 11486553
    [No Abstract]   [Full Text] [Related]  

  • 11. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.
    Mueller M; de la Peña A; Derendorf H
    Antimicrob Agents Chemother; 2004 Feb; 48(2):369-77. PubMed ID: 14742182
    [No Abstract]   [Full Text] [Related]  

  • 12. Should quinolones be used in the treatment of bacterial infections in neutropenic patients?
    Piddock LJ; Dalhoff A
    J Antimicrob Chemother; 1993 Nov; 32(5):771-4. PubMed ID: 8125842
    [No Abstract]   [Full Text] [Related]  

  • 13. Sequential or switch treatment - which criteria should be fulfilled?
    Shah PM
    Int J Antimicrob Agents; 2000 Nov; 16(3):301-2. PubMed ID: 11091052
    [No Abstract]   [Full Text] [Related]  

  • 14. [Tosufloxacin tosilate].
    Shimada K
    Jpn J Antibiot; 1990 Apr; 43(4):583-602. PubMed ID: 2199687
    [No Abstract]   [Full Text] [Related]  

  • 15. The future of the quinolones.
    Andriole VT
    Drugs; 1999; 58 Suppl 2():1-5. PubMed ID: 10553697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Quinolones. Gyrase inhibitors].
    Höffler D
    Internist (Berl); 1994 May; 35(5):484-9. PubMed ID: 8021119
    [No Abstract]   [Full Text] [Related]  

  • 17. In vitro activity and clinical efficacy of ciprofloxacin in otorhinolaryngeal infections.
    Speciale A; Blandino G; Caccamo F; Serra A
    Drugs; 1995; 49 Suppl 2():403-5. PubMed ID: 8549378
    [No Abstract]   [Full Text] [Related]  

  • 18. Focus on severe infections.
    Laupland KB; Paiva JA; Timsit JF
    Intensive Care Med; 2017 Jul; 43(7):1033-1036. PubMed ID: 28501950
    [No Abstract]   [Full Text] [Related]  

  • 19. [Which partner for the betalactam agent in empiric combined therapy? I Fluoroquinolone].
    Bedos JP
    Ann Fr Anesth Reanim; 2004 Jun; 23(6):636-8. PubMed ID: 15234734
    [No Abstract]   [Full Text] [Related]  

  • 20. [Fluoroquinolones--antibacterial activity, pharmacokinetics and indications for a new group of chemotherapeutic drugs].
    Naumann P; Dopp C
    Internist (Berl); 1989 Jan; 30(1):20-31. PubMed ID: 2646237
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.